CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
liothyroninedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02506751
NCT02506751Phase 1Completed
CompareCT.gov

A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS

Johns Hopkins University·interventional·Posted Jul 23, 2015·Updated Feb 12, 2018

In Brief

A Phase 1 clinical trial evaluating liothyronine for Multiple Sclerosis, Relapsing-Remitting and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 23, 2015
Enrollment StartJul 1, 2015
Primary CompletionSep 18, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.9 years ago

Interventions

liothyroninedrug

All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.